When Markets Fall, Pharma Rises: 3 Large-Cap Pharma Stocks at ALL TIME HIGH Despite Sensex at 75,000 — And Why Titan Biotech Ltd Could Be the Next Lupin
Video: Owner-Operator Companies — Founder-Led Multibaggers (Hindi)
March 25, 2026
The Contrarian Investor’s Playbook: Why Geopolitical Panics Create the Best Buying Opportunities for Indian Value Investors
March 25, 2026
Capital Flows to Safety During Uncertainty
During times of geopolitical tension, war, and global uncertainty, smart capital always shifts to defensive sectors. And in India’s stock market, there is no sector more defensive and resilient than Pharma.
If you look at the broader Indian market right now, the Sensex is struggling around 75,000 levels. Many popular stocks across sectors like IT, banking, real estate, and auto are 20-40% below their highs. Retail investors are frustrated, scared, and confused.
But look at what is happening in pharma. While everyone else is bleeding, pharma stocks are quietly marching to ALL TIME HIGHS. This is not a coincidence — this is how markets have always worked. When uncertainty rises, capital flows to essential, non-cyclical, defensive businesses — and pharmaceutical companies are at the top of that list.
The Proof Is in the Numbers
Here are 3 large-cap Indian pharma companies trading at or near ALL TIME HIGH right now — while the Sensex sits at just 75,000:
What Do These Numbers Tell Us?
All three pharma giants are within just 1-2% of their 52-week high — essentially at ALL TIME HIGH territory. This is happening when the broader market is struggling, when FIIs are selling, when global tensions are escalating, and when most retail investors are sitting in losses.
This is the power of defensive sectors during uncertain times. Capital does not disappear — it simply moves from risky sectors to safe havens. And pharma is the ultimate safe haven in India.
Now, Here Is Where It Gets Really Interesting — Titan Biotech Ltd
All four companies we are discussing today belong to the pharmaceutical sector. But there is a massive difference in their market capitalization:
Do you see the gap? Lupin has a market cap of over Rs. 1 lakh crore. Aurobindo is at Rs. 75,000+ crores. Even the relatively newer Emcure is at Rs. 30,000+ crores.
And Titan Biotech Ltd? It is still under Rs. 2,000 crores.
This is precisely why the long-term serious wealth generation scope is dramatically higher in Titan Biotech Ltd. When a quality pharma company has a market cap under Rs. 2,000 crores while its sector peers are at Rs. 30,000 to Rs. 1,00,000+ crores, the runway for growth is enormous.
Quality Companies Always Appear Slightly Overpriced — All the Way Up
Here is something I have learned from years of studying the markets: truly quality companies always look slightly overpriced. They looked overpriced 5 years ago, they looked overpriced 2 years ago, and they look overpriced today. And yet, the patient investors who held on have made extraordinary returns.
This is because the market consistently underestimates the long-term compounding ability of quality businesses. What appears expensive today looks like a bargain in hindsight. This has been true for HDFC Bank, Asian Paints, Page Industries, Dmart — and this is true for Titan Biotech Ltd today.
The Rakesh Jhunjhunwala and Warren Buffett Approach
Think about the greatest investors in history. Did Rakesh Jhunjhunwala try to time the market, constantly buying and selling based on whether a stock was slightly overvalued or slightly undervalued? No.
Did Warren Buffett keep entering and exiting his best positions based on short-term overvaluation and undervaluation? Absolutely not.
Both legends followed the same philosophy: Find quality. Buy it. Hold it for decades. They understood that in the long run, the stock price follows the business — and if the business is growing, the stock will create wealth for patient shareholders.
Rakesh Jhunjhunwala and Lupin — A Lesson in Patience
Rakesh Jhunjhunwala bought Lupin approximately 20-25 years ago and held it through thick and thin. During those 20-25 years, Lupin must have been overvalued many times. It must have been undervalued many times. It must have corrected 30-40% during multiple market crashes. There were many moments when the so-called smart thing would have been to sell and rebuy lower.
But Jhunjhunwala did not play that game. He held on because he knew the business was quality, the sector was essential, and the long-term trajectory was upward. Today, Lupin market cap is over Rs. 1 lakh crore — and those who held with him made generational wealth.
Stop Thinking Small — Think Big Picture
Too many investors today are trapped in narrow thinking. They are obsessing over buying Rs. 5-10 lower and selling Rs. 5-10 higher. They spend all day watching charts, trying to catch small moves, and in the process, they miss the massive, life-changing wealth creation that happens over 10-20 years in quality stocks.
Instead of this short-term thinking, zoom out and look at the big picture:
Think of Titan Biotech Ltd as the
NEXT LUPIN
of the Indian Stock Market
Lupin today is at Rs. 1,07,298 crore market cap. Titan Biotech is under Rs. 2,000 crores. Both are pharma. Both serve essential needs. But the gap in market cap represents the gap in opportunity for patient, long-term investors.
Do not be the investor who buys and sells for Rs. 5-10 profit and misses the journey from Rs. 2,000 crore to Rs. 30,000+ crores. Be the investor who, like Jhunjhunwala with Lupin, identifies quality early, invests with conviction, and holds for the long term.
The next 10-20 years belong to those who invest with patience and conviction today.
While others chase Rs. 5-10 moves, the real wealth creators are quietly building positions in quality companies with massive market cap upside.
Think Big. Think Long-Term. Think Titan Biotech Ltd.
Disclaimer: This content is for educational purposes only and does not constitute financial advice. Stock market investments are subject to market risks. Please consult a SEBI-registered financial advisor before making any investment decisions. The author or Multibagger Shares may hold positions in the stocks mentioned. Past performance is not indicative of future results. All data sourced from publicly available financial databases as of March 2026.
Value Investing Education for 200 Million Indian Investors
multibaggershares.com
